Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

OUS Approvals Analysis: Expanded CoreValve Indication And Zika IVDs Among August’s CE Marks

Executive Summary

August was another slow month for announcements of medical device approvals outside the US, but the short list of non-US approvals this month includes a broad range of device-types approved, notably a much-awaited expanded indication for Medtronic’s CoreValve Evolut R, in six different territories.

Advertisement

Related Content

OUS Approvals: Neurostim And Cardiovascular Lead June Surge
BTG Set To Launch First Radiopaque Drug-Eluting Bead In The EU
Zika Assay Reviews Are Testing The Limits Of FDA Capacity, Shuren Says
US FDA Approves First Intermediate-Risk Indication For TAVR
Expanded Indication For Edwards’ Sapien 3 Squarely In Sight
Data And More Data Expected To Drive BTG Towards Triple-Growth Target
Neuro Medtech Investors Have Time (And Money) For The Pain
APPROVALS ANALYSIS: Big Jump In CE Marks, But Slow August For PMAs
BTG snaps up Biocompatibles

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

MT103829

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel